AbbVie Inc. (ABBV) Monday announced a higher response rate than placebo in the phase 2 trial of its investigational Lutikizumab 300 mg, every other week or weekly in patients with severe hidradenitis suppurativa or acne inversa, who had previously failed anti-TNF therapy.
Higher response rates were the primary endpoint. Based on these data, AbbVie will advance its clinical program of lutikizumab in hidradenitis suppurativa to Phase 3.
Hidradenitis suppurativa is a chronic, progressive, and irreversible inflammatory skin disease that can form lumps, abscesses, and scars under the arms, in the groin, and in other areas.
The company said all doses were generally well-tolerated.
For comments and feedback: editorial@rttnews.com